Aliases & Classifications for Cerebellar Disease

Aliases & Descriptions for Cerebellar Disease:

Name: Cerebellar Disease 12 14
Cerebellar Diseases 42 69
Cerebellar Dysfunction 52
Cerebellar Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:2786
MeSH 42 D002526
UMLS 69 C0007760

Summaries for Cerebellar Disease

MedlinePlus : 41 when you play the piano or hit a tennis ball you are activating the cerebellum. the cerebellum is the area of the brain that controls coordination and balance. problems with the cerebellum include cancer genetic disorders ataxias - failure of muscle control in the arms and legs that result in movement disorders degeneration - disorders caused by brain cells decreasing in size or wasting away treatment of cerebellar disorders depends on the cause. in some cases, there is no cure but treatment may help with symptoms. nih: national institute of neurological disorders and stroke

MalaCards based summary : Cerebellar Disease, also known as cerebellar diseases, is related to leukodystrophy, adult-onset, autosomal dominant and cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, and has symptoms including ataxia, back pain and cerebellar ataxia. An important gene associated with Cerebellar Disease is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are GABAergic synapse and Myometrial Relaxation and Contraction Pathways. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include cerebellum, brain and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Cerebellar Disease

Diseases related to Cerebellar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 leukodystrophy, adult-onset, autosomal dominant 10.9
2 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 10.8
3 cerebellar ataxia 10.8
4 ataxia, cerebellar, cayman type 10.8
5 spinocerebellar ataxia 13 10.8
6 polyglucosan body disease, adult form 10.8
7 cowden syndrome 1 10.7
8 dandy-walker syndrome 10.5
9 spinocerebellar ataxia 17 10.5
10 spinocerebellar ataxia, autosomal recessive 7 10.5
11 spinocerebellar ataxia 5 10.5
12 spinocerebellar ataxia 2 10.5
13 spinocerebellar ataxia 8 10.5
14 machado-joseph disease 10.5
15 spinocerebellar ataxia 15 10.5
16 spinocerebellar ataxia 7 10.5
17 spinocerebellar ataxia 6 10.5
18 mannosidosis, alpha-, types i and ii 10.5
19 spinocerebellar ataxia 10 10.5
20 spinocerebellar ataxia 1 10.5
21 spinocerebellar ataxia 34 10.5
22 spinocerebellar ataxia, autosomal recessive 8 10.5
23 cerebral sclerosis similar to pelizaeus-merzbacher disease 10.2 ATM CACNA1A ZIC1
24 ciliary dyskinesia, primary, 18 10.2 ATXN3 ATXN7 CACNA1A
25 spinocerebellar ataxia, autosomal recessive 3 10.2 ATXN3 ATXN7 CACNA1A
26 blastomycosis 10.2 ATP2B3 CACNA1A
27 locked-in syndrome 10.2 ATP2B3 CACNA1A
28 otosclerosis 4 10.2 PDYN PLEKHG4
29 sialuria 10.1 APTX SACS SETX
30 pulmonary hypertension, primary, 2 10.1 APTX SACS SETX
31 branchiootorenal syndrome 1, with or without cataracts 10.1 APTX SETX
32 autotopagnosia 10.1 APTX ATM SETX
33 deafness, autosomal recessive 7 10.1 APTX CACNA1A SETX
34 cystic echinococcosis 10.1 ATP2B3 ATXN2 ATXN7
35 hypophosphatemic rickets with hypercalciuria 10.1 APTX SACS SETX
36 hypocalcemia, autosomal dominant 2 10.1 ATXN3 ATXN7 CACNA1A PDYN
37 whiplash 10.1 ATXN2 ATXN3
38 proteus syndrome, somatic 10.1 ATXN2 ATXN3 ATXN7 CACNA1A
39 spastic paraplegia 50, autosomal recessive 10.0 ATXN3 ATXN7 CACNA1A PLEKHG4 SPTBN2
40 adams-oliver syndrome 4 10.0 ATXN2 ATXN7 PDYN
41 spinocerebellar ataxia type 16 10.0 ATM COQ8A SETX
42 holoprosencephaly 9.9 ATXN2 ATXN3 ATXN7 CACNA1A PPP2R2B
43 epileptic encephalopathy, early infantile, 21 9.9 ATXN2 ATXN3 ATXN7 CACNA1A PPP2R2B
44 osteoporosis 9.9 ATXN2 ATXN3 ATXN7 CACNA1A PPP2R2B
45 hypogonadotropic hypogonadism 3 with or without anosmia 9.9 ATXN10 ATXN2 PDYN PPP2R2B
46 hypotrichosis 1 9.9 KCNC3 PDYN PRKCG
47 chromosome 9p deletion syndrome 9.9 ITPR1 KCNC3 SPTBN2
48 mental retardation with spastic paraplegia 9.9 ATXN7 COQ8A SACS
49 lissencephaly 6, with microcephaly 9.8 ATXN3 ATXN7 CACNA1A PDYN PLEKHG4 SACS
50 charcot-marie-tooth disease, axonal, type 2l 9.7 ATXN2 ATXN3 ATXN7 CACNA1A ITPR1 PDYN

Graphical network of the top 20 diseases related to Cerebellar Disease:



Diseases related to Cerebellar Disease

Symptoms & Phenotypes for Cerebellar Disease

UMLS symptoms related to Cerebellar Disease:


ataxia, back pain, cerebellar ataxia, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, adiadochokinesis, dysdiadochokinesis, vertigo/dizziness, sleeplessness, cerebellar ataxia/dyskinesia

MGI Mouse Phenotypes related to Cerebellar Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 ATM ATXN2 ATXN3 ATXN7 CACNA1A GAD1
2 homeostasis/metabolism MP:0005376 9.73 APTX ATM ATXN2 ATXN3 CACNA1A GAD1
3 nervous system MP:0003631 9.4 SPTBN2 ZIC1 ATM ATXN2 ATXN3 ATXN7

Drugs & Therapeutics for Cerebellar Disease

Drugs for Cerebellar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 349)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
3
Dopamine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
4
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
5
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
6
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Amantadine Approved Phase 4 768-94-5 2130
9
Sertraline Approved Phase 4 79617-96-2 68617
10
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
11
Metformin Approved Phase 4 657-24-9 14219 4091
12
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
13 insulin Phase 4
14 Estradiol valerate Phase 4 979-32-8
15 Analgesics Phase 4,Phase 1,Phase 2
16 Mitogens Phase 4,Phase 2,Phase 3
17
Serotonin Phase 4,Phase 2 50-67-9 5202
18 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1
19 Serotonin Agents Phase 4,Phase 2
20 Adrenergic Agents Phase 4
21 Serotonin Uptake Inhibitors Phase 4
22 Adrenergic Agonists Phase 4
23 Adrenergic alpha-2 Receptor Agonists Phase 4
24 Adrenergic alpha-Agonists Phase 4
25 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Contraceptive Agents Phase 4,Phase 2
27 Sympatholytics Phase 4
28 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
29 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Estradiol 17 beta-cypionate Phase 4
36 Estradiol 3-benzoate Phase 4
37 Estrogens Phase 4,Phase 2
38 Polyestradiol phosphate Phase 4
39 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Antidepressive Agents, Second-Generation Phase 4
41 Insulin, Globin Zinc Phase 4
42 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Antihypertensive Agents Phase 4,Phase 2
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1
46 interferons Phase 4,Phase 3,Phase 2
47 Chelating Agents Phase 4,Phase 1,Phase 2
48 Muscarinic Antagonists Phase 4
49 Cholinergic Agents Phase 4,Phase 2,Phase 3
50 Cholinergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 344)
id Name Status NCT ID Phase
1 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
3 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4
4 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4
5 Evaluation of Stress Disorders Completed NCT00050804 Phase 4
6 Neuroimaging of the Effects of Concerta in the Treatment of ADHD Completed NCT00778310 Phase 4
7 MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine Completed NCT00809055 Phase 4
8 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Recruiting NCT02733679 Phase 4
9 Randomized Trial of Erythropoietin During Cerebral Malaria Unknown status NCT00697164 Phase 2, Phase 3
10 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
11 Posterior Compression Distraction Reduction (CDR)Technique in the Treatment of BI-AAD Unknown status NCT02463630 Phase 3
12 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
13 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
14 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3
15 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3
16 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3
17 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3
18 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3
19 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3
20 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3
21 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3
22 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3
23 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3
24 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3
25 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3
26 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3
27 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3
28 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3
29 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3
30 A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed NCT01662882 Phase 2, Phase 3
31 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3
32 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3
33 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3
34 Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery Completed NCT00438087 Phase 3
35 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Recruiting NCT02889302 Phase 3
36 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Recruiting NCT02333305 Phase 3
37 EDS in Ataxia Telangiectasia Patients Recruiting NCT02770807 Phase 3
38 Trial in Adult Subjects With Spinocerebellar Ataxia Recruiting NCT02960893 Phase 2, Phase 3
39 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Active, not recruiting NCT01236560 Phase 2, Phase 3
40 Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) Active, not recruiting NCT01378273 Phase 3
41 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Active, not recruiting NCT01346267 Phase 3
42 Lateral Cord Stimulation as a New Treatment for Refractory Spastic Cerebral Palsy Not yet recruiting NCT02199015 Phase 2, Phase 3
43 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3
44 Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus Terminated NCT01092546 Phase 3
45 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Unknown status NCT02039206 Phase 2
46 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
47 Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia Unknown status NCT01958177 Phase 1, Phase 2
48 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
49 4-Aminopyridine in Episodic Ataxia Type 2 Unknown status NCT01543750 Phase 2
50 Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors Unknown status NCT00313521 Phase 2

Search NIH Clinical Center for Cerebellar Disease

Cochrane evidence based reviews: cerebellar diseases

Genetic Tests for Cerebellar Disease

Anatomical Context for Cerebellar Disease

MalaCards organs/tissues related to Cerebellar Disease:

39
Cerebellum, Brain, Eye, Testes, Tongue, Thalamus

Publications for Cerebellar Disease

Articles related to Cerebellar Disease:

(show top 50) (show all 88)
id Title Authors Year
1
Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. ( 27957507 )
2017
2
Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease. ( 27307499 )
2016
3
The effect of a task-specific locomotor training strategy on gait stability in patients with cerebellar disease: a feasibility study. ( 27216372 )
2016
4
Automated cerebellar lobule segmentation with application to cerebellar structural analysis in cerebellar disease. ( 26408861 )
2015
5
Assessment of postural stability in patients with cerebellar disease using gyroscope data. ( 26118512 )
2015
6
Acquired Esotropia in Cerebellar Disease: A Case Series Illustrating Misdiagnosis as Isolated Lateral Rectus Paresis and Progression Over Time. ( 27928333 )
2015
7
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. ( 25985846 )
2015
8
Training balance with opto-kinetic stimuli in the home: a randomized controlled feasibility study in people with pure cerebellar disease. ( 25082955 )
2014
9
Neuro-ophthalmic manifestations of cerebellar disease. ( 25439294 )
2014
10
Clinical manifestations of cerebellar disease. ( 25439285 )
2014
11
Torpedo formation and Purkinje cell loss: modeling their relationship in cerebellar disease. ( 24590661 )
2014
12
Effects of balance and gait rehabilitation in cerebellar disease of vascular or degenerative origin. ( 24398721 )
2014
13
Effects of task constraints on obstacle avoidance strategies in patients with cerebellar disease. ( 23022155 )
2013
14
Disturbed vestibular-neck interaction in cerebellar disease. ( 23081756 )
2013
15
Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. ( 22140200 )
2012
16
Balance rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative cerebellar disease. ( 23232167 )
2012
17
Dichotic listening test in patients with chronic cerebellar disease. ( 22133971 )
2012
18
Effects of cerebellar disease on sequences of rapid eye movements. ( 21385592 )
2011
19
Spike removal through multiscale wavelet and entropy analysis of ocular motor noise: a case study in patients with cerebellar disease. ( 21262262 )
2011
20
Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. ( 22072678 )
2011
21
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. ( 21157217 )
2011
22
Vestibulo-cerebellar disease impairs the central representation of self-orientation. ( 21431098 )
2011
23
Aphasia and neglect are uncommon in cerebellar disease: negative findings in a prospective study in acute cerebellar stroke. ( 20680538 )
2010
24
Long-term effects of coordinative training in degenerative cerebellar disease. ( 20737551 )
2010
25
Longitudinal tracking of gait and balance impairments in cerebellar disease. ( 20544808 )
2010
26
Intensive coordinative training improves motor performance in degenerative cerebellar disease. ( 19864636 )
2009
27
Time estimation in Parkinson's disease and degenerative cerebellar disease. ( 18580578 )
2008
28
Reduced saccadic resilience and impaired saccadic adaptation due to cerebellar disease. ( 18184318 )
2008
29
Clinical manifestation of focal cerebellar disease as related to the organization of neural pathways. ( 18439215 )
2008
30
The Croonian Lectures On The Clinical Symptoms Of Cerebellar Disease And Their Interpretation. Lecture I. 1922. ( 17510914 )
2007
31
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17404205 )
2007
32
The Croonian Lectures on the clinical symptoms of cerebellar disease and their interpretation. Lecture II. 1922. ( 17566247 )
2007
33
Commentary on 'Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture I. The Lancet 1922;202 (Vol. 1 for 1922):1178-1182, and Holmes G. Clinical symptoms of cerebellar disease and their interpretation. Lecture II. The Lancet 1922;202 (Vol. 1 for 1922):1232-1237'. ( 17566248 )
2007
34
Clinical symptoms of cerebellar disease and their interpretation. ( 18041661 )
2007
35
Pediatric periodic alternating gaze deviation with midline cerebellar disease. ( 17280848 )
2007
36
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. ( 17000981 )
2006
37
Cerebellar disease alters the axis of the high-acceleration vestibuloocular reflex. ( 16033941 )
2005
38
Diagnostic approach to cerebellar disease in children. ( 16417854 )
2005
39
Asymmetry of the pitch vestibulo-ocular reflex in patients with cerebellar disease. ( 15826988 )
2005
40
Studies of eccentric gaze stability: effects of pitch head position on horizontal gaze-holding in patients with cerebellar disease. ( 15827030 )
2005
41
Cerebellar disease and disease characterized by dysmetria or tremors. ( 15203226 )
2004
42
Single-neuron analysis of human thalamus in patients with intention tremor and other clinical signs of cerebellar disease. ( 11929926 )
2002
43
Dissociation of habit-learning in Parkinson's and cerebellar disease. ( 11970808 )
2002
44
Cerebellar-subcortical circuits and mania in cerebellar disease. ( 11207338 )
2001
45
Absence of a common functional denominator of visual disturbances in cerebellar disease. ( 10545398 )
1999
46
Non-motor associative learning in patients with isolated degenerative cerebellar disease. ( 10050897 )
1999
47
Directional abnormalities of vestibular and optokinetic responses in cerebellar disease. ( 10372073 )
1999
48
Delayed cerebellar disease and death after accidental exposure to dimethylmercury. ( 9614258 )
1998
49
Romberg sign: sensory dysfunction, not cerebellar disease. ( 9442758 )
1998
50
Orthostatic tremor associated with a pontine lesion or cerebellar disease. ( 9748075 )
1998

Variations for Cerebellar Disease

Expression for Cerebellar Disease

Search GEO for disease gene expression data for Cerebellar Disease.

Pathways for Cerebellar Disease

GO Terms for Cerebellar Disease

Cellular components related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.86 APTX ATM ATXN10 ATXN2 ATXN3 ATXN7
2 axon GO:0030424 9.46 GAD1 KCNC3 SACS SETX
3 dendrite GO:0030425 9.1 ATXN10 CACNA1A KCNC3 PDYN PRKCG SACS

Biological processes related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.02 ATXN3 CACNA1A GAD1 PDYN PRKCG
2 response to pain GO:0048265 8.96 CACNA1A PRKCG

Molecular functions related to Cerebellar Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.13 APTX ATM GAD1
2 calcium ion transmembrane transporter activity GO:0015085 8.62 ATP2B3 ITPR1

Sources for Cerebellar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....